Back to news

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Globe Newswire•16/11/2026•07:15 ET
1

Key Highlights

  • ➤BLA submission completed seeking accelerated approval of nomlabofusp for Friedreich’s ataxia
  • ➤$128.7 million cash, equivalents and securities; runway projected into late Q2 2027
  • ➤U.S. approval targeted mid-2027, with launch targeted for Q3 2027 if approved
  • ➤Third-quarter net loss $31.1 million, or $0.29 per share, versus $47.7 million
  • ➤FORWARD-FA global confirmatory Phase 3 study continues enrolling patients

Expert Statements

Carole Ben-Maimon, Chief Executive Officer of Larimar Therapeutics

“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community.”

Carole Ben-Maimon, Chief Executive Officer of Larimar Therapeutics

“The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”

Carole Ben-Maimon, Chief Executive Officer of Larimar Therapeutics

“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”

Carole Ben-Maimon, Chief Executive Officer of Larimar Therapeutics

“We are energized by progress across our regulatory, clinical and commercial plans and focused on bringing nomlabofusp to adults and pediatric patients with FA as a therapy designed to address the underlying cause of the disease and potentially alter its course.”

* Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause of disease

* Previously disclosed FDA alignment on key BLA elements, including willingness to consider skin frataxin as a potential novel surrogate endpoint

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in